Budget Amount *help |
¥17,290,000 (Direct Cost: ¥13,300,000、Indirect Cost: ¥3,990,000)
Fiscal Year 2020: ¥5,590,000 (Direct Cost: ¥4,300,000、Indirect Cost: ¥1,290,000)
Fiscal Year 2019: ¥5,720,000 (Direct Cost: ¥4,400,000、Indirect Cost: ¥1,320,000)
Fiscal Year 2018: ¥5,980,000 (Direct Cost: ¥4,600,000、Indirect Cost: ¥1,380,000)
|
Outline of Final Research Achievements |
The calcineurin/NFAT (nuclear factor of activated T cells) pathway plays an essential role in carcinogenesis and metastatic potential of breast cancer. However, the molecular mechanism of the antiproliferative effect of calcineurin inhibition is unknown. We have found that calcineurin inhibition delays cell cycle progression in G1/S and promotes cyclin D1 degradation by inhibiting dephosphorylation of Thr286. Overexpression of cyclin D1 partially rescued the delayed progression of G1/S, indicating that cyclin D1 is an important factor downstream of calcineurin inhibition.
|